126 results about "Treatment efficacy" patented technology

The invention belongs to the technical field of medical image processing, and particularly relates to an esophageal cancer treatment effect and survival combined prediction method and system based on multiple modalities, and the method comprises the steps: obtaining a preoperative CT image and Hamp of an esophageal squamous cell carcinoma patient; e, the dyed digital pathological image, transcriptome data and clinical diagnosis and treatment information are preprocessed and subjected to feature extraction, and radiomics embedding representation, pathomics embedding representation and pipeline branch embedding representation are obtained respectively; the radiomics embedded representation, the pathomics embedded representation and the pipeline branch embedded representation are aligned and input into a multi-modal fusion module based on a multi-head self-attention mechanism for feature fusion, and fusion feature representation is generated; and based on the fusion feature representation, synchronously outputting a curative effect prediction result and a survival prediction result by using a multi-task output module, and evaluating model prediction performance by using a curative effect evaluation index and a survival analysis index.

The present disclosure, in some aspects, provides one or more biomarkers (e.g., plasma biomarkers or circulating biomarkers) for Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, a biomarker (e.g., plasma biomarkers or circulating biomarkers) described herein is regulated by DUX4. Methods (e.g., non-invasive methods) of using the biomarkers, e.g., for detection (e.g., early detection) and monitoring patient as well as treatment efficacy are also provided. The present disclosure, in other aspects, provides one or more biomarkers (e.g., transcriptome biomarkers) for Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, a biomarker (e.g., transcriptome biomarkers) described herein is regulated by DUX4. Methods of using the biomarkers, e.g., for detection (e.g., early detection) and monitoring patient as well as treatment efficacy are also provided.

The invention discloses a treatment monitoring method and system for a percutaneous ear vagus nerve stimulation device, and the method comprises the steps: carrying out the multi-source treatment situation monitoring of a target user in a treatment course, obtaining the multi-source treatment situation monitoring data, and constructing a multi-mode treatment situation feature; real-time treatment situation analysis is carried out according to the multi-mode treatment situation features, and real-time treatment situation analysis information is generated; performing dynamic state classification based on the real-time treatment situation analysis information, evaluating the treatment condition of the target user in the current treatment course, and generating a treatment regulation and control scheme to perform treatment management and control on the current treatment course when an abnormal treatment condition exists; and constructing a treatment situation prediction model, obtaining the regulated and controlled multi-mode treatment situation characteristics, generating a floating regulation and control boundary in combination with the treatment situation prediction model, and dynamically correcting the diagnosis and treatment regulation and control scheme by using the floating regulation and control boundary to ensure the curative effect and treatment safety. The treatment effect can be accurately perceived; and the treatment safety is ensured.

This invention discloses an automatic segmentation and scoring method and system for FDG PET-CT lesions in lymphoma, belonging to the field of medical image analysis technology. It aims to improve the segmentation accuracy of lymphoma lesions and the objectivity of the Deauville score. First, standardized uptake values ​​are calculated for FDG PET images, and lymph node morphological features are extracted from CT images based on multi-scale Hessian enhancement filtering to construct a dual-modality PET-CT image pair. Then, a dual-channel depth network is used to extract anatomical structural features and metabolic distribution features respectively. Cross-modal gating fusion is used to suppress physiological uptake interference, outputting preliminary lesion segmentation results. Next, three-dimensional connected component analysis is performed on the segmentation mask, and metabolic heterogeneity index is extracted by combining kurtosis and Haar wavelet multi-scale energy. A graph attention network is used to identify key lesions. Finally, the ratio of key lesions to standardized liver uptake values ​​is combined with the metabolic heterogeneity index to correct the Deauville score, achieving automation from lesion detection to treatment efficacy evaluation.

The invention provides a molecular probe targeting EDB-FN as well as a preparation method and application of the molecular probe. The structural formula of the molecular probe targeting EDB-FN is shown in the specification, according to the molecular probe targeting EDB-FN, the probe is based on a cyclic peptide probe with Lys-Glu side chain lactam bridge conformation fixed, the connection mode of a DOTA chelating agent is optimized, and the clinical transformation bottlenecks that an existing probe is poor in stability, low in affinity, insufficient in targeting specificity, poor in diagnosis and treatment integration compatibility and the like are solved. The probe can be used for early diagnosis and molecular imaging research of tumors, and provides a reliable basis for tumor malignancy degree evaluation and treatment effect monitoring.

Disclosed herein are methods for increasing sensitivity of a cancer cell to alternating electric fields by administering an AKT inhibitor, a mammalian target of rapamycin (mTOR) inhibitor, a Phosphatidylinositol 3-Kinase (PI3K) inhibitor, and / or a Glycogen synthase kinase 3β (GSK3β) inhibitor. Disclosed are methods of increasing treatment efficacy comprising applying alternating electric fields to a target site of the subject for a period of time, the alternating electric fields having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an mTOR inhibitor, AKT inhibitor, PI3K inhibitor, or GSK3β inhibitor to the subject. Disclosed are methods of reducing viability of cancer cells using alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength in combination with either an mTOR inhibitor, AKT inhibitor, PI3K inhibitor, or GSK3β inhibitor and / or a composition or compound that increases cyclin D1. Disclosed are methods of increasing apoptosis of a cancer cell comprising exposing the cancer cell to alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength; and exposing the cancer cell to a PI3K inhibitor.

Disclosed herein are compositions and methods for treating cancer, specifically extensive-stage small-cell lung cancer (ES-SCLC), through the administration of a combination therapy. In some embodiments, the method comprises administering plinabulin, one or more immune checkpoint inhibitors, including but not limited to pembrolizumab, and a regimen of etoposide with a platinum-based agent (EP). The disclosed methods enhance tumor reduction, prolong progression-free survival, and improve overall treatment efficacy compared to traditional therapies.

The invention discloses a colorectal cancer treatment effect evaluation method, system and equipment based on SPP1 + TAMs. According to the application, the high heterogeneity of the TAM in the colorectal cancer and the metastatic microenvironment thereof is systematically revealed from three dimensions of spatial distribution, metabolic characteristics and functional states. On the basis, the invention provides a method for evaluating the treatment effect of the multi-kinase inhibitor and / or the anti-PD-1 therapy medicine on the colorectal cancer based on SPP1 + TAMs, a medicine screening method, a system, equipment and the like, so that a doctor is assisted in evaluating the treatment effect of a patient suffering from the colorectal cancer, and a clinician is guided to formulate an individualized treatment scheme for the patient; meanwhile, a new thought is provided for treatment of colorectal cancer.

Waveform characteristics of pulses in a pulse train configured to cause pulsed field tissue ablation may be varied in a manner that improves electromagnetic compatibility while retaining treatment efficacy. Such waveform characteristics may include pulse-to-pulse initiation intervals, inter-pulse delays, pulse on-times, pulse widths, inter-phase delays in the case of biphasic pulses, or a combination thereof. Such waveform characteristics may be varied in a random manner. Variations of waveform characteristics may be bounded by minimum, maximum, or both minimum and maximum differences between various pulses or pulse groups, or between various pulse trains or pulse train groups, for example, to help ensure sufficient stability of treatment signal waveforms while allowing sufficient variability, for example, to improve electromagnetic compatibility.

The invention relates to a method and device for predicting the curative effect of an image heterogeneity region fusion technology based on a graph network, and belongs to the technical field of intelligent medical treatment and medical image analysis. The method comprises the following steps: firstly, dividing a tumor and a region around the tumor in a medical image into a plurality of non-connected sub-regions as graph nodes, and generating a comprehensive feature representation fusing a local image feature and a node type embedding vector for each node; then, defining edges between nodes based on a spatial distance threshold value, and constructing a graph structure including intra-tumor, peritumor and cross-boundary connection; and finally, inputting the graph structure into a graph neural network model for training to obtain a curative effect prediction model. According to the method, the complex spatial topological relation between the tumor heterogeneity areas is explicitly modeled through the graph structure, the core problems of spatial information loss and insufficient heterogeneity modeling in the prior art are solved, and the accuracy and robustness of treatment effect prediction are remarkably improved.

Described herein are particle-driven radiogenomics systems and methods that can be used to identify imaging features for prediction of intratumoral and interstitial nanoparticle distributions in cancers (e.g., in low grade and / or high-grade brain cancers (e.g., gliomas, e.g., primary gliomas)). In certain embodiments, the systems and methods described herein extract and combine quantitative multi-dimensional data generated from structural, functional, and / or metabolic imaging. In certain embodiments, the combined multidimensional data is linked to intratumoral and interstitial nanoparticle distributions. For example, this linked data can be used to determine quantitative functional-metabolic multimodality particle-based imaging features and to predict treatment efficacy. These techniques provide an improved quantitative ability to measure treatment response and determine tumor progressions compared to traditional size-based imaging methods.

A system and method of determining efficacy of treatment by at least one processor may include receiving, from at least one camera, images depicting motion of an animal that may be treated with a predetermined substance of interest. Said processor may extract from the images, a plurality of motion features representing motion of at least one specific body part of the animal, and apply a dimensionality reduction algorithm on the plurality of motion features, to obtain a latent vector representing the plurality of motion features in a latent space. The latent vector may include a plurality of latent features. Said processor may subsequently calculate a value of a behavioral indicator, representing a behavior of the animal, based on the latent features of the latent vector, and determine efficacy of the treatment based on the behavioral indicator value.

The invention discloses an application of a T cell subset in improving the treatment effect of AK112. The T cell subset is XCL1 + CCL3 + CD8 + T cells. The invention relates to an application of a specific T cell subset in improving the curative effect of AK112, a T cell agonist and AK112 are combined for use, and by synergistically activating the T cell function and reversing the immunosuppression microenvironment, the single drug resistance of AK112 is effectively overcome, the continuous remission time is remarkably prolonged, the treatment response is deepened, the applicable patient group is expanded, and meanwhile, the toxicity risk is reduced. The invention further develops a full-spectrum flow cytometry kit containing 13 antibodies, 13 key markers of the T cell subgroup can be simultaneously detected by one tube, patients sensitive to evoximab treatment (i.e., high expression of the subgroup) can be efficiently screened out, and a convenient tool is provided for accurate medication.

The invention provides a traditional Chinese medicine extract with a folliculitis treatment effect, a preparation method of the traditional Chinese medicine extract and prepared bacteriostatic shampoo, and belongs to the technical field of daily necessities. The traditional Chinese medicine extract is prepared from the following raw materials in parts by mass: 5 to 20 parts of rhizoma coptidis, 5 to 20 parts of cortex phellodendri, 5 to 20 parts of radix scutellariae, 5 to 20 parts of vinegar frankincense, 5 to 20 parts of vinegar myrrh, 5 to 20 parts of radix et rhizoma rhei, 5 to 20 parts of rhizoma polygoni cuspidati, 5 to 20 parts of radix stemonae and 5 to 20 parts of herba taraxaci. By optimizing the compatibility and extraction process of a traditional Chinese medicine formula and combining the modern preparation technology, the invention aims to provide a traditional Chinese medicine hair washing therapeutic agent which is efficient in permeation, long-acting in bacteriostasis, safe, mild and strong in cleaning power, so as to overcome the defects of current chemical hair washing products in the field of folliculitis treatment.

The invention relates to medicine, and more particularly to therapy, and can be used for treating chronic recurrent infection caused by type 1 and 2 herpes simplex viruses (HSV). According to the proposed method, no sooner than 10-14 days after the subsidence of a repeat flare-up, an extract of aspen bark harvested in the autumn-winter period is administered as an interferon inducer in an amount of 3.7 ml 3 times per day after food and washed down with water at room temperature, the full course of treatment lasting 90 days. The invention provides increased therapeutic efficacy and a reduced frequency and duration of recurrent infection by inducing a high level of (alpha and gamma) interferons in HSV-1 and HSV-2 patients.

This invention discloses a core-shell microneedle with both antibacterial and exudate-absorbing properties, and its preparation method, belonging to the field of microneedle drug delivery systems and acne treatment technology. The microneedle comprises: a core layer containing an exudate-absorbing component for absorbing exudate; and a shell layer covering the core layer, containing a microenvironment-responsive drug delivery unit and antibacterial nanoparticles loaded within the drug delivery unit. The drug delivery unit responds to the microenvironment of the acne lesion by releasing the antibacterial nanoparticles. This invention combines baicalein and surfactant into nanoparticles, loaded into a ROS-responsive shell layer formed by TSPBA and polyvinyl alcohol. Sodium polyglutamate is introduced into the core layer as an exudate-absorbing component. The core-shell microneedle is prepared by a two-step centrifugation method. This invention solves the problems of poor drug permeability, uncontrollable release, and exudate affecting treatment efficacy in traditional acne treatments. It achieves targeted drug release and exudate adsorption synergistic effects on acne lesions, improves drug bioavailability, reduces systemic side effects, and is suitable for the treatment of acne, especially inflammatory and purulent acne.

This invention discloses a coherent electrical stimulation method for idiopathic scoliosis combined with exercise therapy, belonging to the field of electrical stimulation methods for idiopathic scoliosis. It aims to address the problem of how to dynamically adjust stimulation parameters based on individual differences to improve treatment efficacy. The method includes acquiring raw image sequences of the patient's spine through MRI scans, preprocessing the raw image sequences to construct a three-dimensional geometric model of the spine, configuring simulated electrical property parameters for the tissue structures, and then adding coherent electrical surface electrodes to the model. The electrode placement area on the three-dimensional geometric model of the spine is initially defined, and a coherent electrical stimulation signal is generated using a function generator. A comprehensive evaluation index value is calculated through finite element analysis to dynamically adjust the coherent electrical stimulation signal. Based on the coherent electrical stimulation signal parameters and its comprehensive evaluation index value, a coherent electrical stimulation scheme is determined, and ultrasound-guided technology is used to locate the electrode positions and implement coherent electrical stimulation therapy.

The invention provides a depression-related electroencephalogram frequency band self-adaption method and system based on Fourier attention of physiological constraints, and belongs to the technical field of electroencephalogram signal processing and emotion recognition. The method comprises the following steps: constructing a physiological constraint frequency mask focused on alpha, theta and beta wavebands; dynamic adjustment of frequency sub-bands is realized by using a learnable Gaussian smoothing mechanism; a physiological constraint Fourier attention mechanism is embedded in the SE module, and end-to-end reweighting is carried out on frequency spectrum and channel features; fourier parameters are optimized through back propagation, and signal reconstruction is realized in combination with inverse Fourier transform. The system further comprises a convolutional neural network structure and a full connection module which are used for extracting electroencephalogram features and outputting depression states and treatment response results. The method has frequency band specificity, self-adaptability and interpretability, improves the accuracy of electroencephalogram depression recognition and evaluation, and is suitable for scenes such as mental disease auxiliary diagnosis and treatment effect prediction.

The application provides application of serum sIL-2R as an ADAM10 inhibitor companion diagnostic marker and a corresponding kit, including two core application scenarios: before treatment, screening of a patient population with high activity of an ADAM10-sIL-2R pathway and most likely to benefit from ADAM10 inhibitor treatment by detecting the serum sIL-2R level of the patient; during and after treatment, evaluating the inhibition effect of the ADAM10 inhibitor on the target pathway and the treatment efficacy by dynamically monitoring the change of the serum sIL-2R level; the liquid companion diagnostic strategy will provide an indispensable supporting tool for the precise application of the ADAM10 inhibitor in pancreatic cancer, and significantly improve the precision and effectiveness of clinical medication.

This invention provides a nanocomposite material with a core-shell structure. The nanocomposite material comprises: ZnO nanoparticles as the core; mesoporous silica as the shell coating the surface of the ZnO nanoparticles; an antibiotic loaded within the pores of the mesoporous silica; hyperbranched polylysine modified on the surface of the mesoporous silica; and a pH-responsive coating material as the outermost layer. The nanocomposite material provided by this invention enables precise targeted drug release in the colon, simultaneously addressing multiple factors leading to CDI recurrence, such as biofilm protection, spore storage, microbial disruption, and mucosal damage, through a sequential synergistic mechanism of "membrane disruption-bactericidal-spore inhibition-repair," thereby improving treatment efficacy.

Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

The invention provides an application of a transcription factor PU.1 inhibitor or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating ulcerative colitis, and belongs to the technical field of biological medicines. According to the invention, intervention is carried out from the upstream of an inflammation network through a small-molecule inhibitor specifically targeting a core transcription factor PU.1, and the multi-dimensional and synergistic treatment effect on ulcerative colitis is realized by regulating and controlling the functions of intestinal immune cells and maintaining the integrity of an intestinal barrier and the steady state of intestinal flora.

This invention provides a covered stent and a stent assembly. The covered stent includes a first segment and two second segments respectively disposed at both axial ends of the first segment. The covered stent includes a bare stent and a covering. The bare stent includes a helical structure extending from one second segment through the first segment to the other second segment, and the helical structure has a greater ascending angle in the first segment than in the second segment. The covering covers the circumferential surface of the bare stent. The covered stent is used in a stent assembly as a branch stent for treating lesions involving the aortic arch, and it can well adapt to the anatomical structure of the aortic arch, improving treatment efficacy.

This invention discloses a PKPD-guided method for treating porcine Pasteurella multocida with antibiotics. YDMS injection is used as the antibiotic, administered intramuscularly to pigs infected with Pasteurella multocida. The dosing regimen is adjusted based on in vivo PK / PD target values. The minimum inhibitory concentration (MIC) of YDMS against Pasteurella multocida is 0.06 μg / mL. PK / PD monitoring is performed using a combination of colloidal gold rapid detection and quantitative real-time PCR. This invention clarifies the three-level PK / PD target values ​​of YDMS against Pasteurella multocida and uses AUIC as the core quantitative indicator, avoiding the blindness of traditional empirical dosing. This ensures precise matching of drug concentration and infection severity, effectively reducing the risk of infection aggravation due to insufficient medication or cumulative toxicity caused by overdose, and significantly improving the consistency of treatment efficacy.

Described herein are various implementations of systems and methods for accessing and modulating tissue (for example, systems and methods for accessing and ablating nerves or other tissue within or surrounding a vertebral body to treat chronic lower back pain). Assessment of vertebral endplate degeneration or defects (e.g., pre-Modic changes) to facilitate identification of treatment sites and protocols are also provided in several embodiments. Several embodiments comprise the use of biomarkers to confirm or otherwise assess ablation, pain relief, efficacy of treatment, etc. Some embodiments include robotic elements for, as an example, facilitating robotically-controlled access, navigation, imaging, and / or treatment.

This application relates to a bile filtration and collection device with heat preservation for bile reinfusion, belonging to the field of medical device technology. The bile filtration and collection device with heat preservation for bile reinfusion of this application includes a stirring assembly, a heating assembly, a filtering assembly, and a nutrient assembly. The stirring assembly includes a stirring drum and a stirrer, with the stirrer configured to rotate within the inner cavity of the stirring drum. The heating assembly includes a heating base disposed below the stirring drum for heating the bile within the drum. The upper end of the filtering assembly communicates with a bile drainage bag, and the lower end communicates with the inner cavity of the stirring drum for filtering the bile. The nutrient assembly is disposed around the periphery of the stirring drum for delivering nutrients into the drum. The bile filtration and collection device with heat preservation for bile reinfusion provided by this application utilizes the filtering assembly, nutrient assembly, stirring assembly, and heating assembly to perform bile filtration, nutrient supplementation, stirring, and heating, improving the convenience and comfort of bile reinfusion and enhancing the patient's treatment efficacy and comfort.

The invention discloses a liver-targeted therapeutic drug based on I-type photodynamic COF as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method comprises the following steps: firstly, synthesizing a novel I-type photosensitizer, modifying imine type COF with the photosensitizer to obtain a series of COF-E with I-type photodynamic capability, then loading a chemotherapeutic drug, and modifying a targeting molecule on the surface of a material through a pi-pi accumulation effect. The biocompatibility and cytotoxicity of the obtained liver tumor targeted nano therapeutic drug are evaluated through the cellular level. The liver tumor targeted therapeutic drug has good stability, can be triggered to release by a tumor microenvironment, and can play a synergistic therapeutic role of type I photodynamic therapy and chemotherapy; in addition, the compound has a good treatment effect in a subcutaneous hypoxia solid tumor model, and is expected to be applied to clinical research.

This invention relates to a method and system for prognostic assessment of ICI retreatment or rechallenge, the system comprising: (1) a storage device storing information including the patient's SII-PNI score before undergoing ICI retreatment or rechallenge; (2) a prediction device that predicts the patient's prognosis and / or treatment efficacy based on the patient's SII-PNI score; and (3) an output device that outputs the predicted prognosis and / or treatment efficacy. The assessment method and system of this invention can conveniently and effectively assess and predict prognosis and / or treatment efficacy, helping physicians and patients decide whether to choose ICI retreatment or rechallenge therapy.

The invention discloses a traditional Chinese medicine composition for bone fracture and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine formulas and preparation thereof, and the traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: angelica sinensis, liquorice, dipsacus root, rheum officinale, frankincense, pawpaw, ground beetle, fructus psoraleae, achyranthes bidentata and borax. The preparation method comprises the following steps: weighing all the medicinal materials according to the proportion, classifying, and respectively carrying out impurity removal and cleaning treatment; performing drying; crushing the special medicinal materials one by one; hard and large medicinal materials are pre-crushed; uniformly mixing the pre-crushed medicinal materials with the residual uncrushed medicinal materials, and performing fine crushing; uniformly mixing the powder obtained by fine crushing with the powder of the special medicinal materials; and screening to obtain the powdery medicinal material with the required granularity. The traditional Chinese medicine composition provided by the invention has a relatively good treatment effect, and the provided preparation method can keep active ingredients in the medicinal materials and improve the medicine effect; the loss of effective components is reduced; the preparation process is easy to control and the product quality is stable.